Macrolides in community-acquired pneumonia: Does the bell toll for thee?

Chest

Volumn 128, Issue 3, 2005, Pages 1089-1093

  Granowitz, Eric V ^a,b,c   Brown, Richard B ^a,b,c  

^a Tufts University School of Medicine ^*

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZALIDE; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

CHLAMYDOPHILA PNEUMONIAE; COMMUNICABLE DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG USE; EDITORIAL; EPIDEMIC; GRAM NEGATIVE BACTERIUM; HOSPITAL DISCHARGE; HUMAN; MORTALITY; OUTPATIENT CARE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 24944547402     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.3.1089     Document Type: Editorial

References (32)

1. Osler W. The principles and practice of medicine. 4th ed. New York, NY: D. Appleton, 1901; 108
2. Chanock RM, Rifkind D, Dravetz JM, et al. Respiratory disease in volunteers infected with Eaton agent: a preliminary report, Proc Natl Acad Sci U S A 1961; 47:887-890
3. Chanock RM, Hayflick L, Barile MF. Growth on artificial medium of an agent associated with atypical pneumonia and its identification as a PPLO. Proc Natl Acad Sci U S A 1962; 48:41-49
4. Fraser DW, Tsai T, Ornstein W, et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297:1189-1197
5. Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalization. Arch Intern Med 1997; 157:1709-1718
6. Niederman MS, Cambell GD, Bass JR Jr. Guidelines for the management of patients with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am J Respir Crit Care Med 1993; 148:1418-1426
7. Niederman MS, Mandell LA, Anzueto A. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754
8. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-1433
9. Ray W, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089-1096
10. Vergis EN, Indorf A, File TM, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients. Arch Intern Med 2000; 160:1294-1300
11. Feldman RB, Rhee DC, Wong JY, et al. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia. Arch Intern Med 2003; 163:1718-1726
12. Drehobl MA, deSalvo MC, Lewis DE, et al. Single-dose azithromycin microspheres versus clarithromycin XL for the treatment of mild to moderate community-acquired pneumonia [abstract]. In: Proceedings of the 44th Interscience Conference on Antibiotics and Antimicrobial Chemotherapy. Washington, DC: ASM Press, 2004; L-660
13. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-1842
14. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440-444
15. Plouffe JF, Breiman RF, Fields BS, et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect Dis 2003; 37:1475-1480
16. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002; 24:1292-1308
17. Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004; 38:S16-S23
18. Carratala J, Fernandez-Sabe N, Ortega L, et al. Outpatient care compared with hospitalization for community-acquired pneumonia. Ann Intern Med 2005; 142:165-172
19. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-760
20. Yu VL, Greenberg RN, Zadeikis N, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125:2135-2139
21. Sabrià M, Pedro-Botot ML, Gòmez J, et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005; 128:1401-1405
22. Mundy LM, Oldach D, Auwaeter PG, et al. Implications for macrolide treatment in community-acquired pneumonia. Chest 1998; 113:1201-1206
23. Mykietiuk A, Carratala J, Fernandez-Sabe N, et al. Clinical outcomes for hospitalized patients with legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005; 40:794-799
24. Garrido RMB, Parra FJE, Frances LA, et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40:800-806
25. Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341:233-239
26. Newhauser MM, Weinstein RA, Rydman, et al. Antibiotic resistance among gram-negative bacillin in US intensive care units. JAMA 2003; 289:885-888
27. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9:1-9
28. Akpunonu B, Michaelis J, Uy CN. Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin Infect Dis 2004; 38: S5-S15
29. MacDougall C, Guglielmo BJ, Maselli J, et al. Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis 2005; 11:380-384
30. Linder JA, Juang ES, Steinman MA, et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2004; 118:259-268
31. Roson B, Carratala J, Fernandez-Sabe N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164:502-508
32. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637-644